Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CANF 
Can Fite Biopharma Ltd ADR (CANF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: CANF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.59% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.05M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 2 | Beta 0.08 | 52 Weeks Range 0.46 - 2.55 | Updated Date 10/23/2025 |
52 Weeks Range 0.46 - 2.55 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2424.75% |
Management Effectiveness
Return on Assets (TTM) -81.86% | Return on Equity (TTM) -264.12% |
Valuation
Trailing PE - | Forward PE 2.97 | Enterprise Value 7895912 | Price to Sales(TTM) 26.88 |
Enterprise Value 7895912 | Price to Sales(TTM) 26.88 | ||
Enterprise Value to Revenue 14.1 | Enterprise Value to EBITDA 0.1 | Shares Outstanding 17072915 | Shares Floating 3966812282 |
Shares Outstanding 17072915 | Shares Floating 3966812282 | ||
Percent Insiders - | Percent Institutions 5.44 |
Upturn AI SWOT
Can Fite Biopharma Ltd ADR
Company Overview
History and Background
Can-Fite BioPharma Ltd. was founded in 2000. It's an Israeli biopharmaceutical company focused on developing small molecule orally bioavailable drugs for inflammatory, autoimmune, and liver diseases. Key milestones include successful clinical trials and partnerships for drug development and commercialization.
Core Business Areas
- Liver Diseases: Developing treatments for liver diseases such as non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).
- Inflammatory Diseases: Developing treatments for inflammatory diseases like psoriasis and rheumatoid arthritis.
- Autoimmune Diseases: Developing treatments for autoimmune conditions.
Leadership and Structure
Dr. Pnina Fishman is the CEO. The company operates with a research and development team, clinical trial management, and commercialization partnerships.
Top Products and Market Share
Key Offerings
- Piclidenoson: An oral A3 adenosine receptor agonist (A3AR) being developed for psoriasis and rheumatoid arthritis. Market share data isn't readily available; the competitive landscape includes established drugs from companies like AbbVie (ABBV) and Amgen (AMGN).
- Namodenoson: An oral A3AR agonist being developed for NASH and HCC. Market share data is currently not applicable as it is still in development. Competitors include companies developing NASH treatments, such as Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with a focus on developing innovative treatments for various diseases.
Positioning
Can-Fite focuses on developing orally bioavailable drugs, offering a potential advantage over injectable therapies. Its competitive advantage lies in targeting the A3AR pathway.
Total Addressable Market (TAM)
The total addressable market for NASH and psoriasis is substantial, estimated to be billions of dollars. Can-Fite is positioned to capture a share of this market with successful development and commercialization of its drugs.
Upturn SWOT Analysis
Strengths
- Orally bioavailable drugs
- Targeting the A3AR pathway
- Focus on unmet medical needs
- Strong patent portfolio
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on partnerships for commercialization
- Clinical trial risks and regulatory hurdles
- History of losses and ongoing need for fundraising.
Opportunities
- Potential for breakthrough therapies in NASH and psoriasis
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Increasing prevalence of target diseases
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory setbacks
- Patent expirations
- Generic competition
Competitors and Market Share
Key Competitors
- ABBV
- AMGN
- MDGL
- VKTX
Competitive Landscape
Can-Fite faces significant competition from larger, more established pharmaceutical companies. Its competitive advantage lies in its focus on oral A3AR agonists, potentially offering a more convenient treatment option.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily characterized by progress in clinical trials and securing partnerships.
Future Projections: Future growth depends on the successful development and commercialization of Piclidenoson and Namodenoson. Analyst estimates vary depending on trial outcomes.
Recent Initiatives: Recent initiatives include advancing clinical trials for psoriasis, rheumatoid arthritis, NASH, and HCC, as well as seeking regulatory approvals.
Summary
Can-Fite BioPharma is a development-stage company with potential in its oral A3AR agonist drugs. Its financial resources are limited, creating risk and possible reward. Success hinges on positive clinical trial outcomes and commercial partnerships. The company should focus on executing strategic partnerships and navigate regulatory pathways successfully to gain market share and to compete with its established competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Third-party financial data providers
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is an estimate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Can Fite Biopharma Ltd ADR
Exchange NYSE MKT | Headquaters - | ||
IPO Launch date 2012-11-06 | CEO and Chief Financial & Operating Officer Mr. Motti Farbstein | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.canfite.com |
Full time employees 5 | Website https://www.canfite.com | ||
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.